logo

Senores Pharmaceuticals Share Price Rises 4.97% After 131% Jump in Q2FY26 Profit

By Shishta Dutta | Published at: Nov 6, 2025 04:34 PM IST

Senores Pharmaceuticals Share Price Rises 4.97% After 131% Jump in Q2FY26 Profit
Open Free Demat Account

By signing up I certify terms, conditions & privacy policy

Ahmedabad, November 6: Senores Pharmaceuticals share price ended today’s trading session in the green, on November 6. At the market close, Senores Pharmaceuticals’ share price ended higher by 4.97%, or 38.10 points, at ₹804.85. The Senores Pharmaceuticals shares made an intraday high of ₹828.90 and an intraday low of ₹780.05. The traded volume for the shares was 22.97 lakh shares, with the company’s market cap at ₹3,531 crore. The stock of Senores Pharmaceuticals has its 52-week high at ₹828.90 and its 52-week low at ₹435.25. The rise in the share price comes after the company posted strong financials for the quarter ended September 30, 2025.

Senores Pharmaceuticals Limited (NSE: SENORES, BSE: 544319 is an Indian company that is engaged in the business of manufacturing pharmaceuticals. The company was established in 2017 and is headquartered in Ahmedabad, Gujarat.

Senores Pharmaceuticals Q2FY26 Financial Highlights

For Q2FY26, Senores Pharmaceuticals reported strong growth, with revenue rising 61% to ₹162 crore and EBITDA surging 113% to ₹50 crore. Profit After Tax (PAT) increased 131% to ₹30 crore. For the first half of FY26 (H1FY26), the company’s revenue grew 66% to ₹300 crore, EBITDA rose 88% to ₹84 crore, and PAT increased 114% to ₹51 crore. The company also generated ₹31.4 crore in operating cash flow during H1FY26, a threefold jump from ₹9 crore in the previous year.

On a segmental basis for Q2FY26, the Regulated Markets remained the largest contributor, accounting for 66.1% of total income, with revenue up 86.9% to ₹107 crore. The Emerging Markets contributed ₹32 crore, while the Branded Generics segment grew more than tenfold to over ₹10 crore.

Investor Takeaway for Senores Pharmaceuticals

Senores Pharmaceuticals reported robust financial results, with revenue up 61% and PAT rising 131%. The strong performance boosted investor demand, helping the shares close higher. It remains to be seen whether the stock can sustain this momentum and finish the week on a positive note.

REF: https://nsearchives.nseindia.com/corporate/SENORES_06112025141034_Initmationofmediareleasesigned.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations

Desktop BannerMobile Banner
Invest Anytime, Anywhere
Play StoreApp Store
Open Free Demat Account Online

By signing up I certify terms, conditions & privacy policy